HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Three-year survival after treatment of a primary pulmonary angiosarcoma].

Abstract
We report an observation of angiosarcoma of the pulmonary artery in a 65-year-old man hospitalized for acute dyspnea revealing a left mass hilaire which arose from the pulmonary artery before the development of obstructive endobronchial extension. The therapeutic sequence associated removal of the lobar bronchus obstruction by interventional endoscopy, chemotherapy using ifosfamide-doxorubicin, complete left pneumonectomy and auxiliary chemotherapy with 2 additional cycles. The patient was free of tumor relapse at nearly 3 years follow-up.
AuthorsP Saint-Blancard, K Hardy, A Bonnichon, R Jancovici, F Vaylet, J Margery
JournalRevue de pneumologie clinique (Rev Pneumol Clin) Vol. 63 Issue 1 Pg. 55-8 (Feb 2007) ISSN: 0761-8417 [Print] France
Vernacular TitleTrois ans de survie après traitement d'un angiosarcome pulmonaire primitif.
PMID17457286 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antibiotics, Antineoplastic
  • Antineoplastic Agents, Alkylating
  • Doxorubicin
  • Ifosfamide
Topics
  • Aged
  • Antibiotics, Antineoplastic (administration & dosage, therapeutic use)
  • Antineoplastic Agents, Alkylating (administration & dosage, therapeutic use)
  • Chemotherapy, Adjuvant
  • Disease-Free Survival
  • Doxorubicin (administration & dosage, therapeutic use)
  • Endoscopy
  • Follow-Up Studies
  • Hemangiosarcoma (diagnosis, diagnostic imaging, drug therapy, pathology, surgery, therapy)
  • Humans
  • Ifosfamide (administration & dosage, therapeutic use)
  • Immunohistochemistry
  • Lung (pathology)
  • Lung Neoplasms (diagnosis, diagnostic imaging, drug therapy, pathology, surgery, therapy)
  • Male
  • Pneumonectomy
  • Positron-Emission Tomography
  • Radiography, Thoracic
  • Time Factors
  • Tomography, X-Ray Computed

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: